Gut microbiota-mediated immunomodulation in tumor

Tumor immunity consists of various types of cells, which serve an important role in antitumor therapy. The gastrointestinal tract is colonized by trillions of microorganisms, which form the gut microbiota. In addition to pathogen defense and maintaining the intestinal ecosystem, gut microbiota also...

Full description

Saved in:
Bibliographic Details
Published inJournal of experimental & clinical cancer research Vol. 40; no. 1; pp. 221 - 20
Main Authors Liu, Xinyi, Chen, Yanjie, Zhang, Si, Dong, Ling
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 03.07.2021
BioMed Central
BMC
Subjects
Adaptive immunity
Analysis
Antibiotics
Antigen presentation
B cells
Cancer
Cytokines
Cytotoxicity
Development and progression
Gastrointestinal Microbiome - drug effects
Gastrointestinal system
Gene expression
Gut microbiota
Health aspects
Humans
Immune checkpoint inhibitor
Immune checkpoint inhibitors
Immunomodulation - immunology
Immunotherapy
Lymphocytes
Medical prognosis
Microbiota
Microbiota (Symbiotic organisms)
Neoplasms - drug therapy
Neutrophils
Pathogenesis
Peptides
Physiological aspects
Review
T cell receptors
Tumor immunity
Tumors
Gut microbiota
Tumor immunity
Antibiotics
Immune checkpoint inhibitor
Online AccessGet full text

Cover

Abstract Tumor immunity consists of various types of cells, which serve an important role in antitumor therapy. The gastrointestinal tract is colonized by trillions of microorganisms, which form the gut microbiota. In addition to pathogen defense and maintaining the intestinal ecosystem, gut microbiota also plays a pivotal role in various physiological processes. Recently, the association between these symbionts and cancer, ranging from oncogenesis and cancer progression to resistance or sensitivity to antitumor therapies, has attracted much attention. Metagenome analysis revealed a significant difference between the gut microbial composition of cancer patients and healthy individuals. Moreover, modulation of microbiome could improve therapeutic response to immune checkpoint inhibitors (ICIs). These findings suggest that microbiome is involved in cancer pathogenesis and progression through regulation of tumor immunosurveillance, although the exact mechanisms remain largely unknown. This review focuses on the interaction between the microbiome and tumor immunity, with in-depth discussion regarding the therapeutic potential of modulating gut microbiota in ICIs. Further investigations are warranted before gut microbiota can be introduced into clinical practice.
AbstractList Tumor immunity consists of various types of cells, which serve an important role in antitumor therapy. The gastrointestinal tract is colonized by trillions of microorganisms, which form the gut microbiota. In addition to pathogen defense and maintaining the intestinal ecosystem, gut microbiota also plays a pivotal role in various physiological processes. Recently, the association between these symbionts and cancer, ranging from oncogenesis and cancer progression to resistance or sensitivity to antitumor therapies, has attracted much attention. Metagenome analysis revealed a significant difference between the gut microbial composition of cancer patients and healthy individuals. Moreover, modulation of microbiome could improve therapeutic response to immune checkpoint inhibitors (ICIs). These findings suggest that microbiome is involved in cancer pathogenesis and progression through regulation of tumor immunosurveillance, although the exact mechanisms remain largely unknown. This review focuses on the interaction between the microbiome and tumor immunity, with in-depth discussion regarding the therapeutic potential of modulating gut microbiota in ICIs. Further investigations are warranted before gut microbiota can be introduced into clinical practice.
Tumor immunity consists of various types of cells, which serve an important role in antitumor therapy. The gastrointestinal tract is colonized by trillions of microorganisms, which form the gut microbiota. In addition to pathogen defense and maintaining the intestinal ecosystem, gut microbiota also plays a pivotal role in various physiological processes. Recently, the association between these symbionts and cancer, ranging from oncogenesis and cancer progression to resistance or sensitivity to antitumor therapies, has attracted much attention. Metagenome analysis revealed a significant difference between the gut microbial composition of cancer patients and healthy individuals. Moreover, modulation of microbiome could improve therapeutic response to immune checkpoint inhibitors (ICIs). These findings suggest that microbiome is involved in cancer pathogenesis and progression through regulation of tumor immunosurveillance, although the exact mechanisms remain largely unknown. This review focuses on the interaction between the microbiome and tumor immunity, with in-depth discussion regarding the therapeutic potential of modulating gut microbiota in ICIs. Further investigations are warranted before gut microbiota can be introduced into clinical practice.Tumor immunity consists of various types of cells, which serve an important role in antitumor therapy. The gastrointestinal tract is colonized by trillions of microorganisms, which form the gut microbiota. In addition to pathogen defense and maintaining the intestinal ecosystem, gut microbiota also plays a pivotal role in various physiological processes. Recently, the association between these symbionts and cancer, ranging from oncogenesis and cancer progression to resistance or sensitivity to antitumor therapies, has attracted much attention. Metagenome analysis revealed a significant difference between the gut microbial composition of cancer patients and healthy individuals. Moreover, modulation of microbiome could improve therapeutic response to immune checkpoint inhibitors (ICIs). These findings suggest that microbiome is involved in cancer pathogenesis and progression through regulation of tumor immunosurveillance, although the exact mechanisms remain largely unknown. This review focuses on the interaction between the microbiome and tumor immunity, with in-depth discussion regarding the therapeutic potential of modulating gut microbiota in ICIs. Further investigations are warranted before gut microbiota can be introduced into clinical practice.
Tumor immunity consists of various types of cells, which serve an important role in antitumor therapy. The gastrointestinal tract is colonized by trillions of microorganisms, which form the gut microbiota. In addition to pathogen defense and maintaining the intestinal ecosystem, gut microbiota also plays a pivotal role in various physiological processes. Recently, the association between these symbionts and cancer, ranging from oncogenesis and cancer progression to resistance or sensitivity to antitumor therapies, has attracted much attention. Metagenome analysis revealed a significant difference between the gut microbial composition of cancer patients and healthy individuals. Moreover, modulation of microbiome could improve therapeutic response to immune checkpoint inhibitors (ICIs). These findings suggest that microbiome is involved in cancer pathogenesis and progression through regulation of tumor immunosurveillance, although the exact mechanisms remain largely unknown. This review focuses on the interaction between the microbiome and tumor immunity, with in-depth discussion regarding the therapeutic potential of modulating gut microbiota in ICIs. Further investigations are warranted before gut microbiota can be introduced into clinical practice. Keywords: Gut microbiota, Tumor immunity, Antibiotics, Immune checkpoint inhibitor
Abstract Tumor immunity consists of various types of cells, which serve an important role in antitumor therapy. The gastrointestinal tract is colonized by trillions of microorganisms, which form the gut microbiota. In addition to pathogen defense and maintaining the intestinal ecosystem, gut microbiota also plays a pivotal role in various physiological processes. Recently, the association between these symbionts and cancer, ranging from oncogenesis and cancer progression to resistance or sensitivity to antitumor therapies, has attracted much attention. Metagenome analysis revealed a significant difference between the gut microbial composition of cancer patients and healthy individuals. Moreover, modulation of microbiome could improve therapeutic response to immune checkpoint inhibitors (ICIs). These findings suggest that microbiome is involved in cancer pathogenesis and progression through regulation of tumor immunosurveillance, although the exact mechanisms remain largely unknown. This review focuses on the interaction between the microbiome and tumor immunity, with in-depth discussion regarding the therapeutic potential of modulating gut microbiota in ICIs. Further investigations are warranted before gut microbiota can be introduced into clinical practice.
ArticleNumber 221
Audience Academic
Author Dong, Ling
Zhang, Si
Liu, Xinyi
Chen, Yanjie
Author_xml – sequence: 1
  givenname: Xinyi
  surname: Liu
  fullname: Liu, Xinyi
– sequence: 2
  givenname: Yanjie
  surname: Chen
  fullname: Chen, Yanjie
– sequence: 3
  givenname: Si
  surname: Zhang
  fullname: Zhang, Si
– sequence: 4
  givenname: Ling
  orcidid: 0000-0001-5995-7673
  surname: Dong
  fullname: Dong, Ling
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34217349$$D View this record in MEDLINE/PubMed
BookMark eNp9kl1rFDEUhgep2A_9A17IgiDeTM3Jd26EUtpaKHij1yGTj90sM5M6yUj992Z3W90tIrlIOHneN8nJe9ocjWn0TfMW0DmA5J8yEER5izC0CJQk7cOL5gQE461SnB_trY-b05zXCHFQoF41x4RiEISqkwZu5rIYop1SF1Mx7eBdNMW7RRyGeUxDcnNvSkzjIo6LMg9pet28DKbP_s3jfNZ8v776dvmlvft6c3t5cddapmhpuWLBYIE6aRgGhyxBgRBlVHBC4E5xS4Opl6ZEKsW8EoEKagEx7jgNnpGz5nbn65JZ6_spDmb6pZOJeltI01KbqUTbe-0sA2k8eB8E9QQ6KSyWDkJnmDfKV6_PO6_7uasvtH4sk-kPTA93xrjSy_RTS8wo5qIafHw0mNKP2eeih5it73sz-jRnXTHJEWZcVfT9M3Sd5mmsraoUwxIrCegvtTT1AXEMqZ5rN6b6ggtMgAHjlTr_B1WH8_XPahpCrPUDwYc9wcqbvqxy6ufND-ZD8N1-R_604ikZFZA7oEYj58kHbWPZJqFeIfYakN6EUO9CqGsI9TaE-qFK8TPpk_t_RL8BsYTcdA
CitedBy_id crossref_primary_10_3389_fmicb_2024_1310444
crossref_primary_10_1016_j_lfs_2024_122487
crossref_primary_10_3389_fimmu_2022_833058
crossref_primary_10_3390_brainsci13081136
crossref_primary_10_3389_fonc_2022_890337
crossref_primary_10_3390_ijms252312982
crossref_primary_10_3389_fimmu_2023_1105293
crossref_primary_10_3390_nu15204408
crossref_primary_10_1038_s41392_023_01619_w
crossref_primary_10_1016_j_scitotenv_2024_172027
crossref_primary_10_30802_AALAS_CM_21_000082
crossref_primary_10_3389_fcimb_2022_953718
crossref_primary_10_1016_j_jbiotec_2024_07_002
crossref_primary_10_3390_cells12050793
crossref_primary_10_3389_fcimb_2023_1211855
crossref_primary_10_3390_ijms24065978
crossref_primary_10_3390_ijms23168991
crossref_primary_10_1007_s12072_021_10260_0
crossref_primary_10_3389_fendo_2022_927959
crossref_primary_10_1111_acel_13807
crossref_primary_10_30802_AALAS_CM_23_000039
crossref_primary_10_3389_fimmu_2022_1030745
crossref_primary_10_3390_cancers17050880
crossref_primary_10_3390_curroncol29050247
crossref_primary_10_1039_D4FO04202F
crossref_primary_10_1007_s10555_024_10215_5
crossref_primary_10_3389_fmicb_2023_1281451
crossref_primary_10_3390_ijms24033051
crossref_primary_10_1016_j_xcrm_2024_101487
crossref_primary_10_3892_mmr_2024_13281
crossref_primary_10_1007_s11010_022_04630_x
crossref_primary_10_1016_j_biopha_2023_115577
crossref_primary_10_3390_biomedicines11061720
crossref_primary_10_1002_cam4_7455
crossref_primary_10_3390_cancers14215369
crossref_primary_10_1007_s11684_022_0927_0
crossref_primary_10_3389_fmicb_2022_1001372
crossref_primary_10_1002_cdt3_36
crossref_primary_10_1016_j_xcrm_2023_101355
crossref_primary_10_1007_s40487_024_00300_8
crossref_primary_10_1016_j_biopha_2023_115484
crossref_primary_10_3389_fimmu_2022_1096551
crossref_primary_10_1016_j_med_2022_12_003
crossref_primary_10_3389_fimmu_2024_1456030
crossref_primary_10_1016_j_compbiolchem_2025_108422
crossref_primary_10_1007_s11255_023_03926_1
crossref_primary_10_1080_08923973_2022_2145966
crossref_primary_10_1186_s40001_024_02072_3
crossref_primary_10_1016_j_bbcan_2023_188943
crossref_primary_10_1073_pnas_2203894119
crossref_primary_10_1515_oncologie_2023_0511
crossref_primary_10_2147_CIA_S414714
Cites_doi 10.1097/MCG.0000000000000046
10.1016/j.cell.2010.03.014
10.1016/j.immuni.2015.01.010
10.1126/science.aac4255
10.1016/j.yexcr.2017.07.009
10.1073/pnas.1712901115
10.1126/science.aad1329
10.1002/hep.30036
10.1126/science.aan3706
10.1200/JCO.2019.37.7_suppl.435
10.1016/j.lungcan.2019.04.008
10.1002/hep.27822
10.1016/j.cell.2016.03.001
10.1136/esmoopen-2020-000803
10.1634/theoncologist.2019-0160
10.1007/s40264-019-00809-2
10.1016/j.intimp.2020.106876
10.1016/j.immuni.2013.12.007
10.1007/s12328-017-0813-5
10.18632/oncoscience.145
10.1038/nature12347
10.1016/j.ccell.2014.09.003
10.1126/science.1217718
10.1016/j.trecan.2017.06.003
10.1126/science.aan4236
10.1126/science.abf3363
10.1158/0008-5472.CAN-18-4108
10.1186/s13073-019-0672-4
10.1016/j.annonc.2020.01.006
10.1186/s12866-016-0738-z
10.7150/jca.47470
10.3748/wjg.v26.i20.2559
10.1038/nature14395
10.1186/s40425-019-0579-z
10.1126/science.1241165
10.1158/0008-5472.CAN-13-2462
10.1002/eji.201948354
10.1038/srep29401
10.1172/JCI93820
10.1016/j.chom.2013.07.007
10.1016/j.immuni.2009.03.019
10.1126/scisignal.2002796
10.1016/j.smim.2017.08.002
10.1158/2326-6066.CIR-16-0348
10.1038/s41467-020-16079-x
10.1186/s13046-019-1271-3
10.1001/jamaoncol.2019.2785
10.1038/nm1663
10.1038/ni.2490
10.1016/j.chom.2016.07.006
10.1038/nrmicro.2017.58
10.1053/jhep.2003.50182
10.1016/j.immuni.2016.09.009
10.1186/s40425-019-0650-9
10.1073/pnas.1921223117
10.1007/s00280-019-03993-1
10.1016/j.jtho.2018.08.395
10.1016/j.jhep.2019.08.016
10.1038/nature12721
10.1038/cr.2016.151
10.1007/s00432-018-2805-3
10.1126/sciimmunol.aat6975
10.1136/gutjnl-2015-310101
10.1126/science.aao3290
10.1016/j.clinre.2014.07.007
10.1111/1348-0421.12210
10.1016/j.neo.2017.08.004
10.1186/s40425-019-0658-1
10.1016/j.jtho.2019.04.007
10.1016/j.lungcan.2019.01.017
10.1016/j.immuni.2014.09.021
10.1158/1078-0432.CCR-15-2463
10.1126/science.1198687
10.1038/s41586-020-2881-9
10.1038/s41416-018-0333-1
10.1126/science.1240527
10.1073/pnas.1518189113
10.1016/j.eururo.2020.04.044
10.1016/j.immuni.2013.07.012
10.7150/ijbs.7823
10.1097/MD.0000000000021788
10.1126/science.1202947
10.1016/j.cmet.2016.05.005
10.1038/s41586-019-0878-z
10.1172/JCI124332
10.1038/nrgastro.2017.72
10.1136/gutjnl-2017-315084
10.3390/ijms20143586
10.1038/ncomms10391
10.1073/pnas.0307317101
10.1038/nature12726
10.3389/fimmu.2016.00550
10.1073/pnas.1108121108
10.1101/gr.126516.111
10.1126/science.1240537
10.1016/j.ebiom.2020.102913
10.1158/1078-0432.CCR-18-3603
10.1016/j.euo.2019.09.001
10.1038/s41586-019-1593-5
10.1093/annonc/mdx108
10.1016/j.ccell.2014.11.009
10.1093/jnci/djt300
10.1002/cam4.2596
10.3389/fimmu.2018.03059
10.1126/science.aan5931
10.18632/oncotarget.24751
10.1126/science.abb5920
10.1093/annonc/mdy103
10.1080/2162402X.2018.1507670
10.1080/2162402X.2019.1568812
10.1111/apt.15604
10.1038/nature18848
10.1038/s41577-019-0127-6
10.1038/nm.4086
10.1080/19490976.2017.1299311
10.1074/jbc.M112.446575
10.1093/ibd/izy182
10.3389/fimmu.2017.01178
10.1158/2159-8290.CD-16-0932
10.4049/jimmunol.1403134
10.1007/s00262-011-0972-z
10.1158/0008-5472.CAN-15-0748
10.1038/srep24838
10.1038/srep15179
10.1038/s41467-019-09884-6
10.1126/science.1160062
10.3389/fimmu.2017.01036
10.1080/2162402X.2019.1665973
10.1038/ni.3518
10.1016/j.immuni.2016.05.002
10.1038/mi.2016.53
10.1007/s00262-020-02536-5
10.1186/s12885-019-6267-z
10.1038/nature22396
10.1038/s41418-019-0312-y
ContentType Journal Article
Copyright COPYRIGHT 2021 BioMed Central Ltd.
2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2021
Copyright_xml – notice: COPYRIGHT 2021 BioMed Central Ltd.
– notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2021
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13046-021-01983-x
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic



MEDLINE

Publicly Available Content Database
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1756-9966
EndPage 20
ExternalDocumentID oai_doaj_org_article_dc518ae1eef74e31b87c28d1fba5ea9e
PMC8254267
A672315156
34217349
10_1186_s13046_021_01983_x
Genre Journal Article
Review
GrantInformation_xml – fundername: National Natural Science Foundation of China
  grantid: 81900482
– fundername: Zhongshan Hospital
  grantid: 2018ZSLC09
– fundername: ;
  grantid: 81900482
– fundername: ;
  grantid: 2018ZSLC09
GroupedDBID ---
0R~
29K
2WC
4.4
5GY
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ADBBV
ADRAZ
ADUKV
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
D-I
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
HMCUK
HYE
IAO
IEA
IHR
IHW
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
TR2
TUS
UKHRP
~8M
-5E
-5G
-A0
-BR
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
7XB
8FK
AZQEC
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c594t-695fa270b8a521d0c30f339a9fd772b96c4fa983438995e97f474c1056d64fe53
IEDL.DBID 7X7
ISSN 1756-9966
0392-9078
IngestDate Wed Aug 27 01:23:00 EDT 2025
Thu Aug 21 13:12:03 EDT 2025
Thu Jul 10 19:31:38 EDT 2025
Fri Jul 25 09:16:29 EDT 2025
Tue Jun 17 21:21:24 EDT 2025
Tue Jun 10 20:38:02 EDT 2025
Thu May 22 21:21:52 EDT 2025
Thu Jan 02 22:57:23 EST 2025
Tue Jul 01 02:26:44 EDT 2025
Thu Apr 24 23:09:42 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Gut microbiota
Tumor immunity
Antibiotics
Immune checkpoint inhibitor
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c594t-695fa270b8a521d0c30f339a9fd772b96c4fa983438995e97f474c1056d64fe53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0001-5995-7673
OpenAccessLink https://www.proquest.com/docview/2552829810?pq-origsite=%requestingapplication%
PMID 34217349
PQID 2552829810
PQPubID 105475
PageCount 20
ParticipantIDs doaj_primary_oai_doaj_org_article_dc518ae1eef74e31b87c28d1fba5ea9e
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8254267
proquest_miscellaneous_2548602569
proquest_journals_2552829810
gale_infotracmisc_A672315156
gale_infotracacademiconefile_A672315156
gale_healthsolutions_A672315156
pubmed_primary_34217349
crossref_citationtrail_10_1186_s13046_021_01983_x
crossref_primary_10_1186_s13046_021_01983_x
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-07-03
PublicationDateYYYYMMDD 2021-07-03
PublicationDate_xml – month: 07
  year: 2021
  text: 2021-07-03
  day: 03
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Journal of experimental & clinical cancer research
PublicationTitleAlternate J Exp Clin Cancer Res
PublicationYear 2021
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References DJ Pinato (1983_CR121) 2019; 5
C Kaderbhai (1983_CR112) 2017; 37
DS Chen (1983_CR3) 2013; 39
T Saito (1983_CR51) 2016; 22
SR Gordon (1983_CR91) 2017; 545
F Huemer (1983_CR116) 2018; 9
EN Baruch (1983_CR137) 2021; 371
S Sun (1983_CR107) 2020; 117
T Kawahara (1983_CR12) 2015; 59
1983_CR58
1983_CR125
AD Kostic (1983_CR59) 2013; 14
1983_CR126
M Uribe-Herranz (1983_CR138) 2020; 130
A Tanaka (1983_CR38) 2017; 27
J Thompson (1983_CR113) 2017; 122
T Tadmor (1983_CR43) 2011; 60
T Hakozaki (1983_CR118) 2019; 17
M Greally (1983_CR124) 2019; 25
N Iida (1983_CR26) 2013; 342
Y Furusawa (1983_CR75) 2013; 504
L Zhou (1983_CR70) 2018; 24
N Arpaia (1983_CR76) 2013; 504
M Kim (1983_CR44) 2017; 8
V Matson (1983_CR36) 2018; 359
1983_CR49
C Fleming (1983_CR52) 2017; 3
M Vetizou (1983_CR32) 2015; 350
1983_CR132
1983_CR133
1983_CR40
1983_CR130
T Tanoue (1983_CR35) 2019; 565
MJ Wolf (1983_CR56) 2014; 26
FA Schildberg (1983_CR87) 2016; 44
ET Orberg (1983_CR21) 2017; 10
1983_CR31
E Lo Presti (1983_CR53) 2017; 5
1983_CR103
K Suzuki (1983_CR47) 2004; 101
1983_CR102
C Groth (1983_CR19) 2019; 120
1983_CR101
1983_CR100
A Schett (1983_CR128) 2020; 85
1983_CR4
C Guillerey (1983_CR23) 2016; 17
N Chaput (1983_CR41) 2017; 28
1983_CR119
L Karyampudi (1983_CR90) 2016; 76
1983_CR114
Y Jin (1983_CR29) 2019; 14
DG DeNardo (1983_CR13) 2019; 19
Y Mishima (1983_CR48) 2019; 129
B Qian (1983_CR15) 2010; 141
1983_CR110
J Ji (1983_CR66) 2015; 62
AA Lalani (1983_CR127) 2020; 3
M Cheng (1983_CR54) 2014; 74
OS Qureshi (1983_CR92) 2011; 332
1983_CR111
G Galli (1983_CR123) 2019; 132
FR Ponziani (1983_CR11) 2019; 69
1983_CR18
1983_CR16
N Singh (1983_CR73) 2014; 40
Y Wu (1983_CR24) 2014; 10
F Wang (1983_CR106) 2018; 115
A Sivan (1983_CR33) 2015; 350
L Zitvogel (1983_CR86) 2016; 165
1983_CR98
L Yu (1983_CR61) 2017; 14
1983_CR97
S Shalapour (1983_CR42) 2015; 521
J Ahn (1983_CR8) 2013; 105
C Alfaro (1983_CR65) 2016; 22
MR Rutkowski (1983_CR60) 2015; 27
O Demaria (1983_CR1) 2019; 574
S Zhao (1983_CR120) 2019; 130
G Cammarota (1983_CR5) 2014; 48
JMT Janco (1983_CR34) 2015; 194
J Li (1983_CR57) 2016; 113
L Macke (1983_CR105) 2020; 51
NR Cohen (1983_CR83) 2013; 14
B Routy (1983_CR94) 2018; 359
TM Loo (1983_CR67) 2017; 7
E Seki (1983_CR64) 2007; 13
AE Frankel (1983_CR95) 2017; 19
S Yoshimoto (1983_CR68) 2013; 499
L Derosa (1983_CR99) 2020; 78
1983_CR88
L Derosa (1983_CR115) 2018; 29
R Daillere (1983_CR27) 2016; 45
RH McMahan (1983_CR79) 2013; 288
C Meyer (1983_CR20) 2011; 108
R Noy (1983_CR14) 2014; 41
1983_CR89
V Gopalakrishnan (1983_CR96) 2018; 359
A Wahlstrom (1983_CR78) 2016; 24
D Davar (1983_CR136) 2021; 371
G D'Alessandro (1983_CR30) 2020; 50
N Tinsley (1983_CR131) 2020; 25
1983_CR81
1983_CR82
Y Rong (1983_CR85) 2017; 358
MR Rutkowski (1983_CR69) 2015; 2
J Abed (1983_CR7) 2016; 20
K Malmberg (1983_CR22) 2017; 31
1983_CR77
C Gur (1983_CR28) 2015; 42
A Agarwal (1983_CR122) 2019; 37S
M Castellarin (1983_CR10) 2012; 22
Q Zhou (1983_CR25) 2020; 26
YH Paik (1983_CR63) 2003; 37
PM Smith (1983_CR74) 2013; 341
S Kawamoto (1983_CR46) 2012; 336
RF Schwabe (1983_CR55) 2020; 72
1983_CR72
F Li (1983_CR39) 2019; 8
M Chalabi (1983_CR129) 2020; 31
1983_CR71
AR Naqash (1983_CR109) 2020; 69
F Sommer (1983_CR135) 2017; 15
B Ricciuti (1983_CR108) 2019; 145
Y Calmus (1983_CR80) 2014; 38
SV Jenkins (1983_CR37) 2019; 79
K Honda (1983_CR45) 2016; 535
K Mima (1983_CR9) 2016; 65
E Vivier (1983_CR2) 2011; 331
S Viaud (1983_CR84) 2013; 342
X Ding (1983_CR6) 2019; 42
M Miyara (1983_CR50) 2009; 30
Y Gao (1983_CR134) 2020; 11
Z Ren (1983_CR62) 2019; 68
I Vujkovic-Cvijin (1983_CR104) 2020; 587
X Mielgo-Rubio (1983_CR117) 2018; 13S
K Wing (1983_CR93) 2008; 322
R Li (1983_CR17) 2019; 26
References_xml – volume: 48
  start-page: 693
  issue: 8
  year: 2014
  ident: 1983_CR5
  publication-title: J Clin Gastroenterol.
  doi: 10.1097/MCG.0000000000000046
– volume: 17
  start-page: 2946
  issue: 3
  year: 2019
  ident: 1983_CR118
  publication-title: Oncol Lett.
– volume: 141
  start-page: 39
  issue: 1
  year: 2010
  ident: 1983_CR15
  publication-title: Cell.
  doi: 10.1016/j.cell.2010.03.014
– volume: 42
  start-page: 344
  issue: 2
  year: 2015
  ident: 1983_CR28
  publication-title: Immunity.
  doi: 10.1016/j.immuni.2015.01.010
– volume: 350
  start-page: 1084
  issue: 6264
  year: 2015
  ident: 1983_CR33
  publication-title: Science.
  doi: 10.1126/science.aac4255
– volume: 358
  start-page: 352
  issue: 2
  year: 2017
  ident: 1983_CR85
  publication-title: Exp Cell Res.
  doi: 10.1016/j.yexcr.2017.07.009
– volume: 115
  start-page: 157
  issue: 1
  year: 2018
  ident: 1983_CR106
  publication-title: P Natl Acad Sci USA.
  doi: 10.1073/pnas.1712901115
– volume: 350
  start-page: 1079
  issue: 6264
  year: 2015
  ident: 1983_CR32
  publication-title: Science.
  doi: 10.1126/science.aad1329
– volume: 69
  start-page: 107
  issue: 1
  year: 2019
  ident: 1983_CR11
  publication-title: Hepatology.
  doi: 10.1002/hep.30036
– volume: 359
  start-page: 91
  issue: 6371
  year: 2018
  ident: 1983_CR94
  publication-title: Science.
  doi: 10.1126/science.aan3706
– volume: 37S
  start-page: 435
  issue: 7
  year: 2019
  ident: 1983_CR122
  publication-title: J Clin Oncol.
  doi: 10.1200/JCO.2019.37.7_suppl.435
– volume: 132
  start-page: 72
  year: 2019
  ident: 1983_CR123
  publication-title: Lung Cancer.
  doi: 10.1016/j.lungcan.2019.04.008
– volume: 62
  start-page: 481
  issue: 2
  year: 2015
  ident: 1983_CR66
  publication-title: Hepatology.
  doi: 10.1002/hep.27822
– volume: 165
  start-page: 276
  issue: 2
  year: 2016
  ident: 1983_CR86
  publication-title: Cell.
  doi: 10.1016/j.cell.2016.03.001
– ident: 1983_CR130
  doi: 10.1136/esmoopen-2020-000803
– volume: 25
  start-page: 55
  issue: 1
  year: 2020
  ident: 1983_CR131
  publication-title: Oncologist.
  doi: 10.1634/theoncologist.2019-0160
– volume: 42
  start-page: 869
  issue: 7
  year: 2019
  ident: 1983_CR6
  publication-title: Drug Safety.
  doi: 10.1007/s40264-019-00809-2
– ident: 1983_CR133
  doi: 10.1016/j.intimp.2020.106876
– volume: 40
  start-page: 128
  issue: 1
  year: 2014
  ident: 1983_CR73
  publication-title: Immunity
  doi: 10.1016/j.immuni.2013.12.007
– ident: 1983_CR4
  doi: 10.1007/s12328-017-0813-5
– volume: 2
  start-page: 239
  issue: 3
  year: 2015
  ident: 1983_CR69
  publication-title: Oncoscience.
  doi: 10.18632/oncoscience.145
– volume: 499
  start-page: 97
  issue: 7456
  year: 2013
  ident: 1983_CR68
  publication-title: Nature.
  doi: 10.1038/nature12347
– volume: 26
  start-page: 549
  issue: 4
  year: 2014
  ident: 1983_CR56
  publication-title: Cancer Cell.
  doi: 10.1016/j.ccell.2014.09.003
– volume: 336
  start-page: 485
  issue: 6080
  year: 2012
  ident: 1983_CR46
  publication-title: Science.
  doi: 10.1126/science.1217718
– volume: 3
  start-page: 561
  issue: 8
  year: 2017
  ident: 1983_CR52
  publication-title: Trends Cancer.
  doi: 10.1016/j.trecan.2017.06.003
– volume: 359
  start-page: 97
  issue: 6371
  year: 2018
  ident: 1983_CR96
  publication-title: Science.
  doi: 10.1126/science.aan4236
– volume: 371
  start-page: 595
  issue: 6529SI
  year: 2021
  ident: 1983_CR136
  publication-title: Science
  doi: 10.1126/science.abf3363
– volume: 79
  start-page: 5999
  issue: 23
  year: 2019
  ident: 1983_CR37
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-18-4108
– ident: 1983_CR98
  doi: 10.1186/s13073-019-0672-4
– volume: 31
  start-page: 525
  issue: 4
  year: 2020
  ident: 1983_CR129
  publication-title: Ann Oncol.
  doi: 10.1016/j.annonc.2020.01.006
– ident: 1983_CR103
  doi: 10.1186/s12866-016-0738-z
– volume: 11
  start-page: 5135
  issue: 17
  year: 2020
  ident: 1983_CR134
  publication-title: J Cancer.
  doi: 10.7150/jca.47470
– volume: 26
  start-page: 2559
  issue: 20
  year: 2020
  ident: 1983_CR25
  publication-title: World J Gastroenterol.
  doi: 10.3748/wjg.v26.i20.2559
– volume: 521
  start-page: 94
  issue: 7550
  year: 2015
  ident: 1983_CR42
  publication-title: Nature.
  doi: 10.1038/nature14395
– ident: 1983_CR110
  doi: 10.1186/s40425-019-0579-z
– volume: 341
  start-page: 569
  issue: 6145
  year: 2013
  ident: 1983_CR74
  publication-title: Science
  doi: 10.1126/science.1241165
– volume: 74
  start-page: 4030
  issue: 15
  year: 2014
  ident: 1983_CR54
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-13-2462
– volume: 50
  start-page: 705
  issue: 5
  year: 2020
  ident: 1983_CR30
  publication-title: Eur J Immunol.
  doi: 10.1002/eji.201948354
– ident: 1983_CR18
  doi: 10.1038/srep29401
– volume: 129
  start-page: 3702
  issue: 9
  year: 2019
  ident: 1983_CR48
  publication-title: J Clin Invest.
  doi: 10.1172/JCI93820
– volume: 14
  start-page: 207
  issue: 2
  year: 2013
  ident: 1983_CR59
  publication-title: Cell Host Microbe.
  doi: 10.1016/j.chom.2013.07.007
– volume: 37
  start-page: 3195
  issue: 6
  year: 2017
  ident: 1983_CR112
  publication-title: Anticancer Res.
– volume: 30
  start-page: 899
  issue: 6
  year: 2009
  ident: 1983_CR50
  publication-title: Immunity.
  doi: 10.1016/j.immuni.2009.03.019
– ident: 1983_CR88
  doi: 10.1126/scisignal.2002796
– volume: 31
  start-page: 20
  issue: SI
  year: 2017
  ident: 1983_CR22
  publication-title: Semin Immunol
  doi: 10.1016/j.smim.2017.08.002
– volume: 5
  start-page: 397
  issue: 5
  year: 2017
  ident: 1983_CR53
  publication-title: Cancer Immunol Res.
  doi: 10.1158/2326-6066.CIR-16-0348
– ident: 1983_CR101
  doi: 10.1038/s41467-020-16079-x
– ident: 1983_CR16
  doi: 10.1186/s13046-019-1271-3
– volume: 5
  start-page: 1774
  issue: 12
  year: 2019
  ident: 1983_CR121
  publication-title: Jama Oncol.
  doi: 10.1001/jamaoncol.2019.2785
– volume: 13
  start-page: 1324
  issue: 11
  year: 2007
  ident: 1983_CR64
  publication-title: Nat Med.
  doi: 10.1038/nm1663
– volume: 14
  start-page: 90
  issue: 1
  year: 2013
  ident: 1983_CR83
  publication-title: Nat Immunol.
  doi: 10.1038/ni.2490
– volume: 20
  start-page: 215
  issue: 2
  year: 2016
  ident: 1983_CR7
  publication-title: Cell Host Microbe.
  doi: 10.1016/j.chom.2016.07.006
– volume: 15
  start-page: 630
  issue: 10
  year: 2017
  ident: 1983_CR135
  publication-title: Nat Rev Microbiol.
  doi: 10.1038/nrmicro.2017.58
– volume: 37
  start-page: 1043
  issue: 5
  year: 2003
  ident: 1983_CR63
  publication-title: Hepatology.
  doi: 10.1053/jhep.2003.50182
– volume: 45
  start-page: 931
  issue: 4
  year: 2016
  ident: 1983_CR27
  publication-title: Immunity.
  doi: 10.1016/j.immuni.2016.09.009
– ident: 1983_CR97
  doi: 10.1186/s40425-019-0650-9
– volume: 117
  start-page: 27509
  issue: 44
  year: 2020
  ident: 1983_CR107
  publication-title: P Natl Acad Sci USA.
  doi: 10.1073/pnas.1921223117
– volume: 85
  start-page: 121
  issue: 1
  year: 2020
  ident: 1983_CR128
  publication-title: Cancer Chemoth Pharm.
  doi: 10.1007/s00280-019-03993-1
– volume: 13S
  start-page: S389
  issue: 10
  year: 2018
  ident: 1983_CR117
  publication-title: J Thorac Oncol
  doi: 10.1016/j.jtho.2018.08.395
– volume: 72
  start-page: 230
  issue: 2SI
  year: 2020
  ident: 1983_CR55
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2019.08.016
– volume: 504
  start-page: 446
  issue: 7480
  year: 2013
  ident: 1983_CR75
  publication-title: Nature.
  doi: 10.1038/nature12721
– volume: 27
  start-page: 109
  issue: 1
  year: 2017
  ident: 1983_CR38
  publication-title: Cell Res.
  doi: 10.1038/cr.2016.151
– volume: 145
  start-page: 479
  issue: 2
  year: 2019
  ident: 1983_CR108
  publication-title: J Cancer Res Clin.
  doi: 10.1007/s00432-018-2805-3
– ident: 1983_CR58
  doi: 10.1126/sciimmunol.aat6975
– volume: 65
  start-page: 1973
  issue: 12
  year: 2016
  ident: 1983_CR9
  publication-title: Gut.
  doi: 10.1136/gutjnl-2015-310101
– volume: 359
  start-page: 104
  issue: 6371
  year: 2018
  ident: 1983_CR36
  publication-title: Science.
  doi: 10.1126/science.aao3290
– volume: 38
  start-page: 550
  issue: 5
  year: 2014
  ident: 1983_CR80
  publication-title: Clin Res Hepatol Gas.
  doi: 10.1016/j.clinre.2014.07.007
– volume: 59
  start-page: 1
  issue: 1
  year: 2015
  ident: 1983_CR12
  publication-title: Microbiol Immunol.
  doi: 10.1111/1348-0421.12210
– volume: 19
  start-page: 848
  issue: 10
  year: 2017
  ident: 1983_CR95
  publication-title: Neoplasia.
  doi: 10.1016/j.neo.2017.08.004
– volume: 122
  start-page: S1997
  issue: 11
  year: 2017
  ident: 1983_CR113
  publication-title: J Thorac Oncol.
– ident: 1983_CR126
  doi: 10.1186/s40425-019-0658-1
– volume: 14
  start-page: 1378
  issue: 8
  year: 2019
  ident: 1983_CR29
  publication-title: J Thorac Oncol.
  doi: 10.1016/j.jtho.2019.04.007
– volume: 130
  start-page: 10
  year: 2019
  ident: 1983_CR120
  publication-title: Lung Cancer.
  doi: 10.1016/j.lungcan.2019.01.017
– volume: 41
  start-page: 866
  issue: 5
  year: 2014
  ident: 1983_CR14
  publication-title: Immunity.
  doi: 10.1016/j.immuni.2014.09.021
– volume: 22
  start-page: 3924
  issue: 15
  year: 2016
  ident: 1983_CR65
  publication-title: Clin Cancer Res.
  doi: 10.1158/1078-0432.CCR-15-2463
– volume: 331
  start-page: 44
  issue: 6013
  year: 2011
  ident: 1983_CR2
  publication-title: Science.
  doi: 10.1126/science.1198687
– volume: 587
  start-page: 448
  issue: 7834
  year: 2020
  ident: 1983_CR104
  publication-title: Nature.
  doi: 10.1038/s41586-020-2881-9
– volume: 120
  start-page: 16
  issue: 1
  year: 2019
  ident: 1983_CR19
  publication-title: Brit J Cancer.
  doi: 10.1038/s41416-018-0333-1
– volume: 342
  start-page: 967
  issue: 6161
  year: 2013
  ident: 1983_CR26
  publication-title: Science.
  doi: 10.1126/science.1240527
– volume: 113
  start-page: E1306
  issue: 9
  year: 2016
  ident: 1983_CR57
  publication-title: P Natl Acad Sci USA.
  doi: 10.1073/pnas.1518189113
– volume: 78
  start-page: 195
  issue: 2
  year: 2020
  ident: 1983_CR99
  publication-title: Eur Urol.
  doi: 10.1016/j.eururo.2020.04.044
– volume: 39
  start-page: 1
  issue: 1
  year: 2013
  ident: 1983_CR3
  publication-title: Immunity.
  doi: 10.1016/j.immuni.2013.07.012
– volume: 10
  start-page: 119
  issue: 2
  year: 2014
  ident: 1983_CR24
  publication-title: Int J Biol Sci.
  doi: 10.7150/ijbs.7823
– ident: 1983_CR100
  doi: 10.1097/MD.0000000000021788
– volume: 332
  start-page: 600
  issue: 6029
  year: 2011
  ident: 1983_CR92
  publication-title: Science.
  doi: 10.1126/science.1202947
– volume: 24
  start-page: 41
  issue: 1
  year: 2016
  ident: 1983_CR78
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2016.05.005
– volume: 565
  start-page: 600
  issue: 7741
  year: 2019
  ident: 1983_CR35
  publication-title: Nature.
  doi: 10.1038/s41586-019-0878-z
– volume: 130
  start-page: 466
  issue: 1
  year: 2020
  ident: 1983_CR138
  publication-title: J Clin Invest.
  doi: 10.1172/JCI124332
– volume: 14
  start-page: 527
  issue: 9
  year: 2017
  ident: 1983_CR61
  publication-title: Nat Rev Gastro Hepat.
  doi: 10.1038/nrgastro.2017.72
– volume: 68
  start-page: 1014
  issue: 6
  year: 2019
  ident: 1983_CR62
  publication-title: Gut.
  doi: 10.1136/gutjnl-2017-315084
– ident: 1983_CR102
  doi: 10.3390/ijms20143586
– ident: 1983_CR111
  doi: 10.1038/ncomms10391
– volume: 101
  start-page: 1981
  issue: 7
  year: 2004
  ident: 1983_CR47
  publication-title: P Natl Acad Sci USA.
  doi: 10.1073/pnas.0307317101
– volume: 504
  start-page: 451
  issue: 7480
  year: 2013
  ident: 1983_CR76
  publication-title: Nature.
  doi: 10.1038/nature12726
– ident: 1983_CR89
  doi: 10.3389/fimmu.2016.00550
– volume: 108
  start-page: 17111
  issue: 41
  year: 2011
  ident: 1983_CR20
  publication-title: P Natl Acad Sci USA.
  doi: 10.1073/pnas.1108121108
– volume: 22
  start-page: 299
  issue: 2
  year: 2012
  ident: 1983_CR10
  publication-title: Genome Res.
  doi: 10.1101/gr.126516.111
– volume: 342
  start-page: 971
  issue: 6161
  year: 2013
  ident: 1983_CR84
  publication-title: Science.
  doi: 10.1126/science.1240537
– ident: 1983_CR72
  doi: 10.1016/j.ebiom.2020.102913
– volume: 25
  start-page: 6160
  issue: 20
  year: 2019
  ident: 1983_CR124
  publication-title: Clin Cancer Res.
  doi: 10.1158/1078-0432.CCR-18-3603
– volume: 3
  start-page: 372
  issue: 3
  year: 2020
  ident: 1983_CR127
  publication-title: Eur Urol Oncol.
  doi: 10.1016/j.euo.2019.09.001
– volume: 574
  start-page: 45
  issue: 7776
  year: 2019
  ident: 1983_CR1
  publication-title: Nature.
  doi: 10.1038/s41586-019-1593-5
– volume: 28
  start-page: 1368
  issue: 6
  year: 2017
  ident: 1983_CR41
  publication-title: Ann Oncol.
  doi: 10.1093/annonc/mdx108
– volume: 27
  start-page: 27
  issue: 1
  year: 2015
  ident: 1983_CR60
  publication-title: Cancer Cell.
  doi: 10.1016/j.ccell.2014.11.009
– volume: 105
  start-page: 1907
  issue: 24
  year: 2013
  ident: 1983_CR8
  publication-title: JNCI-J Natl Cancer I.
  doi: 10.1093/jnci/djt300
– volume: 8
  start-page: 7330
  issue: 17
  year: 2019
  ident: 1983_CR39
  publication-title: Cancer Med-US.
  doi: 10.1002/cam4.2596
– ident: 1983_CR31
  doi: 10.3389/fimmu.2018.03059
– ident: 1983_CR81
  doi: 10.1126/science.aan5931
– volume: 9
  start-page: 16512
  issue: 23
  year: 2018
  ident: 1983_CR116
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.24751
– volume: 371
  start-page: 602
  issue: 6529SI
  year: 2021
  ident: 1983_CR137
  publication-title: Science
  doi: 10.1126/science.abb5920
– volume: 29
  start-page: 1437
  issue: 6
  year: 2018
  ident: 1983_CR115
  publication-title: Ann Oncol.
  doi: 10.1093/annonc/mdy103
– ident: 1983_CR114
  doi: 10.1080/2162402X.2018.1507670
– ident: 1983_CR119
  doi: 10.1080/2162402X.2019.1568812
– volume: 51
  start-page: 505
  issue: 5
  year: 2020
  ident: 1983_CR105
  publication-title: Aliment Pharm Ther.
  doi: 10.1111/apt.15604
– volume: 535
  start-page: 75
  issue: 7610
  year: 2016
  ident: 1983_CR45
  publication-title: Nature.
  doi: 10.1038/nature18848
– volume: 19
  start-page: 369
  issue: 6
  year: 2019
  ident: 1983_CR13
  publication-title: Nat Rev Immunol.
  doi: 10.1038/s41577-019-0127-6
– volume: 22
  start-page: 679
  issue: 6
  year: 2016
  ident: 1983_CR51
  publication-title: Nat Med.
  doi: 10.1038/nm.4086
– volume: 8
  start-page: 392
  issue: 4
  year: 2017
  ident: 1983_CR44
  publication-title: Gut Microbes.
  doi: 10.1080/19490976.2017.1299311
– volume: 288
  start-page: 11761
  issue: 17
  year: 2013
  ident: 1983_CR79
  publication-title: J Biol Chem.
  doi: 10.1074/jbc.M112.446575
– volume: 24
  start-page: 1926
  issue: 9
  year: 2018
  ident: 1983_CR70
  publication-title: Inflamm Bowel Dis.
  doi: 10.1093/ibd/izy182
– ident: 1983_CR82
  doi: 10.3389/fimmu.2017.01178
– volume: 7
  start-page: 522
  issue: 5
  year: 2017
  ident: 1983_CR67
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-16-0932
– volume: 194
  start-page: 2985
  issue: 7
  year: 2015
  ident: 1983_CR34
  publication-title: J Immunol.
  doi: 10.4049/jimmunol.1403134
– volume: 60
  start-page: 609
  issue: 5
  year: 2011
  ident: 1983_CR43
  publication-title: Cancer Immunol Immun.
  doi: 10.1007/s00262-011-0972-z
– volume: 76
  start-page: 239
  issue: 2
  year: 2016
  ident: 1983_CR90
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-15-0748
– ident: 1983_CR71
  doi: 10.1038/srep24838
– ident: 1983_CR40
  doi: 10.1038/srep15179
– ident: 1983_CR49
  doi: 10.1038/s41467-019-09884-6
– volume: 322
  start-page: 271
  issue: 5899
  year: 2008
  ident: 1983_CR93
  publication-title: Science.
  doi: 10.1126/science.1160062
– ident: 1983_CR77
  doi: 10.3389/fimmu.2017.01036
– ident: 1983_CR132
  doi: 10.1080/2162402X.2019.1665973
– volume: 17
  start-page: 1025
  issue: 9
  year: 2016
  ident: 1983_CR23
  publication-title: Nat Immunol.
  doi: 10.1038/ni.3518
– volume: 44
  start-page: 955
  issue: 5
  year: 2016
  ident: 1983_CR87
  publication-title: Immunity.
  doi: 10.1016/j.immuni.2016.05.002
– volume: 10
  start-page: 421
  issue: 2
  year: 2017
  ident: 1983_CR21
  publication-title: Mucosal Immunol.
  doi: 10.1038/mi.2016.53
– volume: 69
  start-page: 1177
  issue: 7
  year: 2020
  ident: 1983_CR109
  publication-title: Cancer Immunol Immun.
  doi: 10.1007/s00262-020-02536-5
– ident: 1983_CR125
  doi: 10.1186/s12885-019-6267-z
– volume: 545
  start-page: 495
  issue: 7655
  year: 2017
  ident: 1983_CR91
  publication-title: Nature.
  doi: 10.1038/nature22396
– volume: 26
  start-page: 2447
  issue: 11
  year: 2019
  ident: 1983_CR17
  publication-title: Cell Death Differ.
  doi: 10.1038/s41418-019-0312-y
SSID ssj0061919
Score 2.521927
SecondaryResourceType review_article
Snippet Tumor immunity consists of various types of cells, which serve an important role in antitumor therapy. The gastrointestinal tract is colonized by trillions of...
Abstract Tumor immunity consists of various types of cells, which serve an important role in antitumor therapy. The gastrointestinal tract is colonized by...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 221
SubjectTerms Adaptive immunity
Analysis
Antibiotics
Antigen presentation
B cells
Cancer
Cytokines
Cytotoxicity
Development and progression
Gastrointestinal Microbiome - drug effects
Gastrointestinal system
Gene expression
Gut microbiota
Health aspects
Humans
Immune checkpoint inhibitor
Immune checkpoint inhibitors
Immunomodulation - immunology
Immunotherapy
Lymphocytes
Medical prognosis
Microbiota
Microbiota (Symbiotic organisms)
Neoplasms - drug therapy
Neutrophils
Pathogenesis
Peptides
Physiological aspects
Review
T cell receptors
Tumor immunity
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NaxUxEA_Sg3gRtVVXq92C4EFCd1--j1WsRagnC72FbD7wgW9X2n3QP9-ZZN_yFkEvXjcT2PySyfyGzAch78AK-ZhQv6PsKA9e0M6HRMFyptAJE5jA3OGrb_Lymn-9ETd7rb4wJqyUBy7AncHsVrvYxpgUj6zttPIrHdrUORGdiXj7gs3bOVPlDgavoDW7FBktz-5afACkGI4AlEYzer8wQ7la_5938p5RWgZM7lmgiyfk8UQd6_Pyy0_Jg9g_Iw-vpsfxQ9J-2Y71Zl0qK42O5qQQIJT1GnNAhs0QplZd9bqvx-1muD0i1xefv3-6pFNHBOqF4SOVRiS3Uk2nHZjd0HjWJMaMA1yBJXdGep4crA9bmhsRjUpccQ8USgbJUxTsOTnohz6-JLU2DpheF5r8uglwKmGETkk32oEX1FSk3QFk_VQuHLtW_LTZbdDSFlAtgGozqPa-Ih_mOb9KsYy_Sn9E3GdJLHSdP8D222n77b-2vyInuGu2ZI3O6mrPpQLmCmRNVuR9lkCFhQV4N-UdAAxY-mohebyQBEXzy-HdybCTot9Z8MjwLVq3ANjpPIwzMXitj8MWZXKnLyFNRV6UgzQvmnHwCRmHEbU4YgtUliP9-kcuA46-_UqqV_8Dxtfk0Sprh6INOyYH4-02vgG2NXZvs2L9BgDFJzc
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEF9KBfFF6ndq1QiCD7Ka3H4_iFSxFuF88qBvy2azaw96iV5zUP97ZzYfNFj6mp2E7C8zmd8wOzOEvAEv5ENE-w6yorz2gla-jhQ8Z6wrYWomsHZ4-UOervj3M3G2R8ZxRwOAlzeGdjhParW9eH_15-8nMPiPyeC1_HBZYnqP4mEDICyaUeCUd8AzKTTUJZ-yChArpEEf4DElRZ4_FtHc-IyZo0r9_P__a19zW_Mjldd81MkBuT-Qy_y414YHZC80D8nd5ZA-f0TKb7su36z73kudo6lsBChnvsYqkXbT1sMwr3zd5N1u024fk9XJ159fTukwM4F6YXhHpRHRLVRRaQeOuS48KyJjxgHywKMrIz2PDvaHQ8-NCEZFrrgHkiVryWMQ7AnZb9omPCO5Ng64YFUXKf9ZxkoJI3SMutAO4qQiI-UIkPVDQ3Gca3FhU2Chpe1BtQCqTaDaq4y8m-753bfTuFX6M-I-SWIr7HSh3f6yg2VZUK9Su1CGEBUPrKy08gtdw_s6EZwJGXmFX832daWTQdtjqYDbAp2TGXmbJFDJYAPeDZUJAAM2x5pJHs0kwRT9fHnUDDtqsoWYDbPVugTAXk_LeCceb2tCu0OZNAtMSJORp70iTZtmHKJGxmFFzVRshsp8pVmfp0bhGP0vpDq8_bWek3uLpPeKFuyI7HfbXXgBTKurXibz-QesSCIR
  priority: 102
  providerName: Scholars Portal
Title Gut microbiota-mediated immunomodulation in tumor
URI https://www.ncbi.nlm.nih.gov/pubmed/34217349
https://www.proquest.com/docview/2552829810
https://www.proquest.com/docview/2548602569
https://pubmed.ncbi.nlm.nih.gov/PMC8254267
https://doaj.org/article/dc518ae1eef74e31b87c28d1fba5ea9e
Volume 40
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9wwDDdbC2MvY99L190yGOxhmCYXf-Vp9Ea7MrgyygrHXozj2N3BLmnvctA_f5LjyxoGfclDrEAsS9ZPliUR8hGskHUe9duJirLaclrZ2lOwnL6ueFkXHHOH5-fi7JJ9X_BFPHDbxGuVuz0xbNR1a_GM_AigLwb9VJ59ub6h2DUKo6uxhcZDso-ly_BKl1wMDhf4BqGxB1hIQRHX75JmlDja5BgSpHhBAUCOKujtyDCF-v3_79J3zNT4CuUdm3T6lDyJYDI97lf_GXngmufk0TyGy1-Q_Nu2S1fLvtZSZ2hIEwGImS4xK6RdtXVs3pUum7Tbrtr1S3J5evLz6xmNPRKo5SXrqCi5N1OZVcqAIa4zW2S-KEoDnAbcXJXCMm9gftjkvOSulJ5JZgFUiVow73jxiuw1bePekFSVBrBfVWch3pn7SnJgqfcqUwb8oiwh-Y5B2sYC4tjH4o8OjoQSumeqBqbqwFR9m5DPwzfXffmMe6lnyPeBEktfhxft-kpHTdIgTrkyLnfOS-aKvFLSTlUN_2u4M6VLyHtcNd3nkQ4KrI-FBCwL8E0k5FOgQBWGCVgTMxGADVgMa0R5OKIE1bPj4Z1k6Kj6G_1PUBPyYRjGL_E6W-PaLdKE3l9clAl53QvSMOmCgZdYMBiRIxEbcWU80ix_h8Lg6O1PhTy4_7feksfTIPeSZsUh2evWW_cOkFVXTYL6TMj-7OT8x8UknE_Ac84UPC9mv_4CEr4jIQ
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqrQRcEG8ChQYJxAFZzcuOfUCohZYt7a4QaqXejOPYsBKblN2sKH-K38iMkyyNkHrrNZ5IznieGc98hLwEL2SsQ_22vKBZaRgtTOkoeE5XFkyWKcPe4cmUj0-zT2fsbIP86Xth8FplbxO9oS5rg__IdyD0xaKfiKN35z8pokZhdbWH0GjF4sj-_gUp2_Lt4Qc431dJcrB_8n5MO1QBapjMGsolczrJo0JocF1lZNLIpanUsDeINAvJTea0FCnCgktmZe6yPDMIUF_yzFlEiQCTv5mlkMqMyObe_vTzl972QzbioUTAJ3OKmUTfpiP4zjLGIiTFKxEQVomUXgxcoUcM-N8vXHKMw0ubl7zgwR1yuwtfw91W3u6SDVvdIzcmXYH-Pok_rppwPmunOzWa-sYUCGrDGfah1PO67ODCwlkVNqt5vXhATq-Ffw_JqKor-5iEQmqINosy8hXW2BU5k0w4JyKhIROLAhL3DFKmG1mOyBk_lE9dBFctUxUwVXmmqouAvFm_c94O7LiSeg_5vqbEYdv-Qb34pjrdVSDAsdA2ttblmU3jQuQmESXsVzOrpQ3INp6aajtX1yZD7fIcomcIGHlAXnsKNBrwAUZ3vQ_ABhy_NaDcGlCCspvhci8ZqjM2S_VPNQLyYr2Mb-IFusrWK6TxaGOMy4A8agVp_dFpBnlpmsFKPhCxAVeGK9Xsux9Fjv8XEp4_uXpb2-Tm-GRyrI4Pp0dPya3E60BOo3SLjJrFyj6DuK4pnnfKFJKv162_fwEsQFuE
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Gut+microbiota-mediated+immunomodulation+in+tumor&rft.jtitle=Journal+of+experimental+%26+clinical+cancer+research&rft.au=Liu%2C+Xinyi&rft.au=Chen%2C+Yanjie&rft.au=Zhang%2C+Si&rft.au=Dong%2C+Ling&rft.date=2021-07-03&rft.pub=BioMed+Central&rft.issn=1756-9966&rft.volume=40&rft.spage=1&rft_id=info:doi/10.1186%2Fs13046-021-01983-x
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-9966&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-9966&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-9966&client=summon